Myocardial Ischemia - Pipeline Review, H2 2017

Myocardial Ischemia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H2 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Ischemia - Overview 7
Myocardial Ischemia - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Myocardial Ischemia - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Myocardial Ischemia - Companies Involved in Therapeutics Development1
Angionetics Inc1
Bayer AG1
Cellmid Ltd2
CohBar Inc2
Lixte Biotechnology Holdings Inc2
NoNO Inc3
Omniox Inc3
Pathfinder Cell Therapy Inc4
Myocardial Ischemia - Drug Profiles5
AB-002 - Drug Profile5
Product Description5
Mechanism Of Action5
R&D Progress5
alferminogene tadenovec - Drug Profile6
Product Description6
Mechanism Of Action6
R&D Progress6
BAY-606583 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CMK-103 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DT-010 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Humanin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
LB-100 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
OMX-4.80 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Pathfinder Cells - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
PMC-6 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
sirolimus - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Myocardial Ischemia - Dormant Projects 47
Myocardial Ischemia - Discontinued Products 49
Myocardial Ischemia - Product Development Milestones 50
Featured News & Press Releases 50
Jan 09,017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease 50
Sep 12,016: Angionetics Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 50
May 11,015: Angionetics Presents At015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 51
Jan7,015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The015 Phacilitate 11th Annual Cell & Gene Therapy Forum 53
Sep 03,014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 55
Aug 13,014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 55
Jun 12,014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The014 BIO International Convention 56
Jan7,014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 56
May 02,013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 57
Nov 19,012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 58
Oct5,012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 60
Mar0,012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 60
Jun 15,011: Cardium Therapeuticss Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 62
Nov 03,010: Cardium Awarded Grant Under QTDP Program 63
Dec 08,006: Cardiums Generx Advances To Phase III Following Meeting With FDA 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List Of Tables

List of Tables
Number of Products under Development for Myocardial Ischemia, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products under Development by Universities/Institutes, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Universities/Institutes, H2 2017 12
Number of Products by Stage and Target, H2 2017 14
Number of Products by Stage and Mechanism of Action, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Myocardial Ischemia - Pipeline by Angionetics Inc, H2 2017 21
Myocardial Ischemia - Pipeline by Bayer AG, H2 2017 21
Myocardial Ischemia - Pipeline by Cellmid Ltd, H2 2017 22
Myocardial Ischemia - Pipeline by CohBar Inc, H2 2017 22
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 23
Myocardial Ischemia - Pipeline by NoNO Inc, H2 2017 23
Myocardial Ischemia - Pipeline by Omniox Inc, H2 2017 23
Myocardial Ischemia - Pipeline by Pathfinder Cell Therapy Inc, H2 2017 24
Myocardial Ischemia - Dormant Projects, H2 2017 47
Myocardial Ischemia - Dormant Projects, H2 2017 (Contd..1), H2 2017 48
Myocardial Ischemia - Discontinued Products, H2 2017 49

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available